Cancer Gene Therapy Market: By Therapy Type (Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer), By End-User (Hospitals and Clinics, Biopharma and Biotechnology Companies, Academic and Research Institutes, Others), and By Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Cancer Gene Therapy Market size was valued at USD 2,688.3 Million in 2023 and is anticipated to grow at a CAGR of 24.3% over 2024-2030. Cancer gene therapy, also known as gene-based cancer therapy or gene transfer therapy, is an innovative approach to treating cancer by modifying or manipulating a patient's own genes to target and combat cancer cells. This therapeutic strategy aims to correct genetic mutations, enhance the body's natural immune response, or introduce therapeutic genes into cancerous cells to inhibit their growth and proliferation. The rising incidence of cancer plays a pivotal role in driving the revenues of the cancer gene therapy market. According to the American Cancer Society, there were an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States in 2022. As the global burden of various types of cancers continues to increase, there is a growing demand for innovative and effective treatment options beyond traditional methods. Cancer gene therapy, with its potential to target specific genetic mutations and mechanisms driving cancer growth, offers a promising avenue for addressing this growing healthcare challenge. Advancements in genetic research play a pivotal role in propelling the cancer gene therapy market forward. As our understanding of the genetic underpinnings of cancer deepens, researchers are uncovering specific genetic mutations and alterations that drive the initiation and progression of various cancer types. This intricate knowledge forms the foundation for the development of gene therapies that can precisely target and manipulate cancer-related genes. Advancements in techniques like next-generation sequencing and genome editing technologies enable scientists to identify and modify these genetic abnormalities with greater precision and efficiency. However, less awareness, and high cost involved in treatment, lack of reimbursement policies for advanced gene therapy methods are restraining the growth of the global market for cancer gene therapy. Meanwhile, increases in funding from various government and non-government organizations, ethical acceptance of gene therapy for the treatment of diseases, and the growing popularity of DNA vaccines create significant opportunities for the growth of the market. Key market players are developing novel gene therapy approaches that can treat different types of cancer. 

 Cancer Gene Therapy Market Key Developments:        

  • In March 2023, Pfizer announced the acquisition of Seagen for a total enterprise value of approximately $43 billion which will enhance Pfizer’s position as a leading company in oncology.
  • In March 2023, Sartorius agreed to acquire Polyplus for 2.4 billion euros to expand its business.

Global Cancer Gene Therapy Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

24.3%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Cancer Gene Therapy Market Dynamics

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. Various factors, such as the increase in the prevalence of cancer, rising government initiatives, increase in funding from various government and non-government organizations, ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines is driving the global cancer gene therapy market. However, less awareness and high cost involved in treatment, Lack of reimbursement policies for advanced gene therapy methods are restraining the growth of the global market for cancer gene therapy.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Cancer Gene Therapy Market Segmentation

By Therapy Type
  • Gene Induced Immunotherapy
  • Oncolytic Virotherapy
  • Gene Transfer
By End User
  • Hospitals and Clinic
  • Biopharma and Biotechnology Companies
  • Academic and Research Institutes
  • Others
By Geography
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions

The Cancer Gene Therapy Market size was valued at USD 2,688.3 million in 2023

The advances in gene therapy for the treatments of rare cancers, continued development of advanced gene editing techniques, particularly CRISPR-Cas9, and integration of immunotherapy stand out as significant trends within the cancer gene therapy market.

Adaptimmune, GlaxoSmithKline, Bluebird bio, Inc., Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBionoGeneTech, SynerGene Therapeutics, and OncoGenex Pharmaceuticals., and others are some of the key market players in the cancer gene therapy market.

1. Executive Summary
2. Global Cancer Gene Therapy Market Introduction
2.1. Global Cancer Gene Therapy Market Taxonomy
2.2. Global Cancer Gene Therapy Market Definitions
2.2.1. Therapy Type
2.2.2. End User
2.2.3. Region
3. Global Cancer Gene Therapy Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Current Trends
3.5. Global Cancer Gene Therapy Market Dynamic Factors - Impact Analysis
3.6. Mergers, Acquisitions, and Collaborations
4. Global Cancer Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Cancer Gene Therapy Market, By Therapy Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1. Gene Induced Immunotherapy
5.1.1. Delivery of Cytokines Gene
5.1.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Delivery of Tumor Antigen Gene
5.1.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.2. Oncolytic Virotherapy
5.2.1. Adenovirus
5.2.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Lentivirus
5.2.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Retro virus
5.2.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.2.4. Adeno Associated Virus
5.2.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.4.3. Market Opportunity Analysis
5.2.5. Herpes Simplex Virus
5.2.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.5.3. Market Opportunity Analysis
5.2.6. Alpha Virus
5.2.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.6.3. Market Opportunity Analysis
5.2.7. Vaccinia Virus
5.2.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.7.3. Market Opportunity Analysis
5.2.8. Simian Virus
5.2.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.8.3. Market Opportunity Analysis
5.2.9. Others
5.2.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.9.3. Market Opportunity Analysis
5.3. Gene Transfer
5.3.1. Naked/Plasmid Vectors
5.3.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.1.3. Market Opportunity Analysis
5.3.2. Electroporation
5.3.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.2.3. Market Opportunity Analysis
5.3.3. Sonoporation
5.3.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3.3. Market Opportunity Analysis
5.3.4. Magnetofection
5.3.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.4.3. Market Opportunity Analysis
5.3.5. Gene gun
5.3.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.5.3. Market Opportunity Analysis
6. Global Cancer Gene Therapy Market, By End User, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1. Hospitals and Clinics
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Biopharma and Biotechnology Companies
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Academic and Research Institutes
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Cancer Gene Therapy Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia Pacific
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. MEA
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Region, 2024 - 2030
8. North America Cancer Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.1. Therapy Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Gene Induced Immunotherapy
8.1.1.1. Delivery of Cytokines Gene
8.1.1.2. Delivery of Tumor Antigen Gene
8.1.2. Oncolytic Virotherapy
8.1.2.1. Adenovirus
8.1.2.2. Lentivirus
8.1.2.3. Retro virus
8.1.2.4. Adeno Associated Virus
8.1.2.5. Herpes Simplex Virus
8.1.2.6. Alpha Virus
8.1.2.7. Vaccinia Virus
8.1.2.8. Simian Virus
8.1.2.9. Others
8.1.3. Gene Transfer
8.1.3.1. Naked/Plasmid Vectors
8.1.3.2. Electroporation
8.1.3.3. Sonoporation
8.1.3.4. Magnetofection
8.1.3.5. Gene gun
8.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Hospitals and Clinics
8.2.2. Biopharma and Biotechnology Companies
8.2.3. Academic and Research Institutes
8.2.4. Others
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.3.1. United States
8.3.2. Canada
8.4. North America Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027
8.5. North America Cancer Gene Therapy Market Dynamics – Trends
9. Europe Cancer Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
9.1. Therapy Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Gene Induced Immunotherapy
9.1.1.1. Delivery of Cytokines Gene
9.1.1.2. Delivery of Tumor Antigen Gene
9.1.2. Oncolytic Virotherapy
9.1.2.1. Adenovirus
9.1.2.2. Lentivirus
9.1.2.3. Retro virus
9.1.2.4. Adeno Associated Virus
9.1.2.5. Herpes Simplex Virus
9.1.2.6. Alpha Virus
9.1.2.7. Vaccinia Virus
9.1.2.8. Simian Virus
9.1.2.9. Others
9.1.3. Gene Transfer
9.1.3.1. Naked/Plasmid Vectors
9.1.3.2. Electroporation
9.1.3.3. Sonoporation
9.1.3.4. Magnetofection
9.1.3.5. Gene gun
9.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Hospitals and Clinics
9.2.2. Biopharma and Biotechnology Companies
9.2.3. Academic and Research Institutes
9.2.4. Others
9.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. UK
9.3.2. Germany
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Europe Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027
9.5. Europe Cancer Gene Therapy Market Dynamics – Trends
10. Asia Pacific Cancer Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
10.1. Therapy Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Gene Induced Immunotherapy
10.1.1.1. Delivery of Cytokines Gene
10.1.1.2. Delivery of Tumor Antigen Gene
10.1.2. Oncolytic Virotherapy
10.1.2.1. Adenovirus
10.1.2.2. Lentivirus
10.1.2.3. Retro virus
10.1.2.4. Adeno Associated Virus
10.1.2.5. Herpes Simplex Virus
10.1.2.6. Alpha Virus
10.1.2.7. Vaccinia Virus
10.1.2.8. Simian Virus
10.1.2.9. Others
10.1.3. Gene Transfer
10.1.3.1. Naked/Plasmid Vectors
10.1.3.2. Electroporation
10.1.3.3. Sonoporation
10.1.3.4. Magnetofection
10.1.3.5. Gene gun
10.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Hospitals and Clinics
10.2.2. Biopharma and Biotechnology Companies
10.2.3. Academic and Research Institutes
10.2.4. Others
10.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. ANZ
10.3.4. Japan
10.3.5. Rest of APAC
10.4. Asia Pacific Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027
10.5. Asia Pacific Cancer Gene Therapy Market Dynamics – Trends
11. Latin America Cancer Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
11.1. Therapy Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Gene Induced Immunotherapy
11.1.1.1. Delivery of Cytokines Gene
11.1.1.2. Delivery of Tumor Antigen Gene
11.1.2. Oncolytic Virotherapy
11.1.2.1. Adenovirus
11.1.2.2. Lentivirus
11.1.2.3. Retro virus
11.1.2.4. Adeno Associated Virus
11.1.2.5. Herpes Simplex Virus
11.1.2.6. Alpha Virus
11.1.2.7. Vaccinia Virus
11.1.2.8. Simian Virus
11.1.2.9. Others
11.1.3. Gene Transfer
11.1.3.1. Naked/Plasmid Vectors
11.1.3.2. Electroporation
11.1.3.3. Sonoporation
11.1.3.4. Magnetofection
11.1.3.5. Gene gun
11.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Hospitals and Clinics
11.2.2. Biopharma and Biotechnology Companies
11.2.3. Academic and Research Institutes
11.2.4. Others
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of LA
11.4. Latin America Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027
11.5. Latin America Cancer Gene Therapy Market Dynamics – Trends
12. MEA Cancer Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
12.1. Therapy Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Gene Induced Immunotherapy
12.1.1.1. Delivery of Cytokines Gene
12.1.1.2. Delivery of Tumor Antigen Gene
12.1.2. Oncolytic Virotherapy
12.1.2.1. Adenovirus
12.1.2.2. Lentivirus
12.1.2.3. Retro virus
12.1.2.4. Adeno Associated Virus
12.1.2.5. Herpes Simplex Virus
12.1.2.6. Alpha Virus
12.1.2.7. Vaccinia Virus
12.1.2.8. Simian Virus
12.1.2.9. Others
12.1.3. Gene Transfer
12.1.3.1. Naked/Plasmid Vectors
12.1.3.2. Electroporation
12.1.3.3. Sonoporation
12.1.3.4. Magnetofection
12.1.3.5. Gene gun
12.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Hospitals and Clinics
12.2.2. Biopharma and Biotechnology Companies
12.2.3. Academic and Research Institutes
12.2.4. Others
12.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Rest of MEA
12.4. MEA Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027
12.5. MEA Cancer Gene Therapy Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Urigen Pharmaceuticals Inc.
13.2.2. GenVec.Inc
13.2.3. Oxford BioMedica
13.2.4. Vical
13.2.5. ANI Pharmaceuticals, Inc.
13.2.6. Genzyme Corporation
13.2.7. Novartis AG
13.2.8. Cell Medica
13.2.9. Cell Genesys Inc.
13.2.10. Adaptimmune Therapeutics plc
13.2.11. Genelux Corporation
14. Research Methodology
15. Key Assumptions and Acronyms
  • Urigen Pharmaceuticals Inc.
  • GenVec.Inc
  • Oxford BioMedica
  • Vical
  • ANI Pharmaceuticals, Inc.
  • Genzyme Corporation
  • Novartis AG
  • Cell Medica
  • Cell Genesys Inc.
  • Adaptimmune Therapeutics plc
  • Genelux Corporation

Adjacent Markets